Search research articles
Contact Us
Filters
Showing results (201-210 of 211) with videos related to
Page
of 22
Sort By:
Chinese Medical Journal
|
November 18, 2011
Prospective, naturalistic study of open-label OROS methylphenidate treatment in Chinese school-aged children with attention-deficit/hyperactivity disorder
Yi Zheng, Yu-Feng Wang, Jiong Qin, et al.
Molecular Cancer Therapeutics
|
May 23, 2024
PKMYT1 Is a Marker of Treatment Response and a Therapeutic Target for CDK4/6 Inhibitor-Resistance in ER+ Breast Cancer
Anran Chen, Beom-Jun Kim, Aparna Mitra, et al.
Nature Cancer
|
February 5, 2022
The CIP2A-TOPBP1 axis safeguards chromosome stability and is a synthetic lethal target for BRCA-mutated cancer
Salomé Adam, Silvia Emma Rossi, Nathalie Moatti, et al.
Molecular Cancer Therapeutics
|
December 16, 2021
RP-3500: A Novel, Potent, and Selective ATR Inhibitor that is Effective in Preclinical Models as a Monotherapy and in Combination with PARP Inhibitors
Anne Roulston, Michal Zimmermann, Robert Papp, et al.
Journal of Medicinal Chemistry
|
July 26, 2022
Discovery of an Orally Bioavailable and Selective PKMYT1 Inhibitor, RP-6306
Janek Szychowski, Robert Papp, Evelyne Dietrich, et al.
Nature Medicine
|
October 28, 2025
A full life cycle biological clock based on routine clinical data and its impact in health and diseases
Kai Wang, Fei Liu, Wei Wu, et al.
Nature Medicine
|
December 11, 2024
Self-improving generative foundation model for synthetic medical image generation and clinical applications
Jinzhuo Wang, Kai Wang, Yunfang Yu, et al.
Nature
|
April 21, 2022
CCNE1 amplification is synthetic lethal with PKMYT1 kinase inhibition
David Gallo, Jordan T F Young, Jimmy Fourtounis, et al.
Journal of Medicinal Chemistry
|
May 16, 2025
Discovery of RP-1664: A First-in-Class Orally Bioavailable, Selective PLK4 Inhibitor
Frédéric Vallée, Matias Casás-Selves, Monica Bubenik, et al.
Journal of Medicinal Chemistry
|
September 8, 2025
The Discovery of RP-2119: A Potent, Selective, and Orally Bioavailable Polθ ATPase Inhibitor
Philippe Mochirian, Robert Papp, Marie-Claude Mathieu, et al.
Page
of 22
Search research articles
Search
Showing results (201-210 of 211) with videos related to
Sort By:
Page
of 22
Chinese Medical Journal
|
November 18, 2011
Prospective, naturalistic study of open-label OROS methylphenidate treatment in Chinese school-aged children with attention-deficit/hyperactivity disorder
Yi Zheng, Yu-Feng Wang, Jiong Qin, et al.
Molecular Cancer Therapeutics
|
May 23, 2024
PKMYT1 Is a Marker of Treatment Response and a Therapeutic Target for CDK4/6 Inhibitor-Resistance in ER+ Breast Cancer
Anran Chen, Beom-Jun Kim, Aparna Mitra, et al.
Nature Cancer
|
February 5, 2022
The CIP2A-TOPBP1 axis safeguards chromosome stability and is a synthetic lethal target for BRCA-mutated cancer
Salomé Adam, Silvia Emma Rossi, Nathalie Moatti, et al.
Molecular Cancer Therapeutics
|
December 16, 2021
RP-3500: A Novel, Potent, and Selective ATR Inhibitor that is Effective in Preclinical Models as a Monotherapy and in Combination with PARP Inhibitors
Anne Roulston, Michal Zimmermann, Robert Papp, et al.
Journal of Medicinal Chemistry
|
July 26, 2022
Discovery of an Orally Bioavailable and Selective PKMYT1 Inhibitor, RP-6306
Janek Szychowski, Robert Papp, Evelyne Dietrich, et al.
Nature Medicine
|
October 28, 2025
A full life cycle biological clock based on routine clinical data and its impact in health and diseases
Kai Wang, Fei Liu, Wei Wu, et al.
Nature Medicine
|
December 11, 2024
Self-improving generative foundation model for synthetic medical image generation and clinical applications
Jinzhuo Wang, Kai Wang, Yunfang Yu, et al.
Nature
|
April 21, 2022
CCNE1 amplification is synthetic lethal with PKMYT1 kinase inhibition
David Gallo, Jordan T F Young, Jimmy Fourtounis, et al.
Journal of Medicinal Chemistry
|
May 16, 2025
Discovery of RP-1664: A First-in-Class Orally Bioavailable, Selective PLK4 Inhibitor
Frédéric Vallée, Matias Casás-Selves, Monica Bubenik, et al.
Journal of Medicinal Chemistry
|
September 8, 2025
The Discovery of RP-2119: A Potent, Selective, and Orally Bioavailable Polθ ATPase Inhibitor
Philippe Mochirian, Robert Papp, Marie-Claude Mathieu, et al.
Page
of 22